Healthcare - Biotechnology - NASDAQ - US
$ 1.59
2.58 %
$ 57.6 M
Market Cap
-3.15
P/E
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.[ Read More ]
The intrinsic value of one NTRBW stock under the base case scenario is HIDDEN Compared to the current market price of 1.59 USD, Nutriband Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart NTRBW
FINANCIALS
2.09 M
REVENUE
-4.87 M
OPERATING INCOME
-5.49 M
NET INCOME
-3.53 M
OPERATING CASH FLOW
-51.8 K
INVESTING CASH FLOW
2.09 M
FINANCING CASH FLOW
443 K
REVENUE
-1.41 M
OPERATING INCOME
-1.71 M
NET INCOME
-1.54 M
OPERATING CASH FLOW
-38.9 K
INVESTING CASH FLOW
-5.14 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Nutriband Inc.
| Current Assets | 1.02 M |
| Cash & Short-Term Investments | 493 K |
| Receivables | 149 K |
| Other Current Assets | 380 K |
| Non-Current Assets | 6.5 M |
| Long-Term Investments | 0 |
| PP&E | 806 K |
| Other Non-Current Assets | 5.69 M |
| Current Liabilities | 999 K |
| Accounts Payable | 680 K |
| Short-Term Debt | 196 K |
| Other Current Liabilities | 123 K |
| Non-Current Liabilities | 79.8 K |
| Long-Term Debt | 79.8 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Nutriband Inc.
| Revenue | 2.09 M |
| Cost Of Revenue | 1.22 M |
| Gross Profit | 862 K |
| Operating Expenses | 5.73 M |
| Operating Income | -4.87 M |
| Other Expenses | 613 K |
| Net Income | -5.49 M |
RATIOS
41.34%
GROSS MARGIN
-233.63%
OPERATING MARGIN
-263.04%
NET MARGIN
-85.20%
ROE
-72.97%
ROA
-72.94%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nutriband Inc.
| Net Income | -5.49 M |
| Depreciation & Amortization | 288 K |
| Capital Expenditures | -51.8 K |
| Stock-Based Compensation | 743 K |
| Change in Working Capital | 223 K |
| Others | 822 K |
| Free Cash Flow | -3.58 M |
Wall Street Analysts Price Targets
Nutriband Inc.
NTRBW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Nutriband Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.
accesswire.com
- 2 weeks ago
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
The approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica ORLANDO, FL / ACCESSWIRE / October 17, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has received approval from the Costa Rica Ministry of Health for the production and marketing of its Mosquito Repellent Patch, designed to reduce the risk of mosquito bites and associated health risks associated with exposure to mosquito bites.
accesswire.com
- 1 month ago
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Founder and Chief Executive Officer Gareth Sheridan and Founder and President Serguei Melnik, who will share insight into the Company's current operations and upcoming milestones.
accesswire.com
- 1 month ago
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch ORLANDO, FL / ACCESSWIRE / September 24, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for patent application entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology. The Aversa™ abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China.
accesswire.com
- 1 month ago
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patch Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products ORLANDO, FL / ACCESSWIRE / September 20, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed a trademark licensing agreement for the use of Bitrex® brand denatonium benzoate as an aversive agent in its lead product, AVERSA™ Fentanyl, an abuse deterrent fentanyl patch. Nutriband's AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
accesswire.com
- 1 month ago
Nutriband Inc. Authorizes $1M Share Buyback Program
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common stock outstanding.
accesswire.com
- 2 months ago
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has reported its financial results for the second quarter ended July 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for the first half of 2025.
accesswire.com
- 2 months ago
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Chairman and President Serguei Melnik and Chief Executive Officer Gareth Sheridan, who will share insight into the Company's current operations and upcoming milestones.
accesswire.com
- 3 months ago
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on July 9, 2024, for trademark application Serial Number 98117984, covering the mark "AVERSA™." The Notice of Allowance signifies that the USPTO is expected to grant a trademark registration for this application following the completion of administrative processes.
accesswire.com
- 4 months ago
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to NDA filing. As previously reported, the Company with its partner Kindeva Drug Delivery completed the feasibility agreement and entered into a commercial development and clinical supply agreement to manufacture product for the human abuse potential clinical study in support of a New Drug Application (NDA) to be submitted to FDA.
accesswire.com
- 4 months ago
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on using penetration pricing to gain a foothold with some of the industry's largest brands and License holders such as KT Tape and Fit For Life Group, who hold licenses for major international brands such as Reebok, Adidas and New Balance.
accesswire.com
- 5 months ago
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement ORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.
accesswire.com
- 6 months ago
8. Profile Summary
Nutriband Inc. NTRBW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 57.6 M
Dividend Yield
0.00%
Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Contact
121 South Orange Avenue, Orlando, FL, 32801
http://nutriband.com
IPO Date
Oct. 1, 2021
Employees
3
Officers
Mr. Tyler Overk
Head of Active Intelligence
Mr. Gareth Sheridan
Founder, Chief Executive Officer & Director
Mr. Serguei Melnik
Founder, President, Company Secretary & Executive Chairman of the Board
Mr. Gerald Goodman
Chief Financial Officer & Chief Accounting Officer
Dr. Alan Smith Ph.D.
Chief Operating Officer & President of 4P Therapeutics
Mr. Michael Myer
President of Pocono Pharmaceutical
Dr. Jeffrey Patrick Pharm.D.
Chief Scientific Officer